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Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq 
Next-Generation Sequencing on Clinical Decision-Making
Tiroid Nodülü Genomik Profillemesi: ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme 
Üzerinde Güncel Rolü
Abstract
In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant 
neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a 
large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis 
in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology. 
Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role 
in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies 
assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules 
with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there 
are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decision-
making in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results 
of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines 
regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.
Keywords: Thyroid cancer, thyroid nodule, genomic profiling, next-generation sequencing, ThyroSeq, molecular testing
Öz
Son yıllarda benign ve malign tiroid neoplazmlarının altında yatan genetik değişiklerle ilgili artan bir farkındalık oluşmuştur. 
Yeni nesil dizinleme [Next-generation sequencing (NGS)] tiroid ince iğne aspirasyon (İİA) örneklerinde çok sayıda genetik 
mutasyonun hızlı tespitine izin veren ve gelişmekte olan bir teknolojidir. Tiroid tümörlerinin hedeflenen mutasyon analizi 
için NGS, İİA ile belirsiz sitoloji saptanan tiroid nodüllerinin tanısında yardımcı olmak için bir araç olarak öne sürülmüştür. 
Ek olarak, tiroid nodülü ve tiroid kanserlerinin genomik test sonuçlarının prognostik etkileri olabilir ve hedefli tedaviler dahil 
olmak üzere uygun tedavi stratejilerinin belirlenmesinde önemli bir rol oynayabilir. Bu yazıda İİA ile belirsiz sitolojisi olan tiroid 
nodüllü hastaların tanı ve tedavisinde ThyroSeq NGS testinin performansını değerlendiren mevcut çalışmaların bir derlemesini 
sunmayı ve bu çalışmalardan elde edilen bulguların klinik pratikte uygulanabilirliğini tartışmayı amaçladık. Her ne kadar erken 
veriler NGS’den elde edilen verilerin tiroid kanserinde prognoz ve tedavi kararı sürecine olası yardımlarını öne sürse de, bu tür 
moleküler testlerin devam eden klinik çalışmaların sonuçları belirlenene kadar, akıllıca kullanılmasını ve dikkatli yorumlanmasını 
öneriyoruz. Son olarak, tiroid nodüllerinin tanısal değerlendirilmesinde NGS ile mutasyon tespiti ile ilgili klinik uygulama 
kılavuzlarından edinilmiş öneriler tartışılmıştır.
Anahtar kelimeler: Tiroid kanseri, tiroid nodülü, genomik profilleme, yeni nesil dizinleme, ThyroSeq, moleküler test
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Introduction
Thyroid nodules are common in the general population 
with higher prevalence in women and in older persons. 
When ultrasound is performed at random in the general 
population 19-68% of individuals are found to harbor one 
or more thyroid nodules (1). While the majority of these 
nodules are not clinically significant 7-15% are malignant 
(2). Paralleling the increased use of imaging techniques 
and of thyroid fine-needle aspiration (FNA) there has been 
dramatic increase worldwide in both the incidence of 
thyroid nodule diagnosis and that of thyroid cancer over 
the past 20-30 years (3,4). 
Several clinical practice guidelines have set forth strategies 
to manage patients who are discovered to have thyroid 
nodules, yet a great deal of controversy still exists as to 
the optimal approach to diagnosis and treatment (5,6). 
The widespread use of high-resolution ultrasonography of 
the neck as well as thyroid FNA has significantly enhanced 
our ability to diagnose malignancy among thyroid nodules, 
however 20-30% of cytology results from thyroid FNA 
fall into one of three indeterminate diagnostic categories 
according to the Bethesda System for Reporting Thyroid 
Cytopathology: Atypia of undetermined significance/
Follicular lesion of undetermined significance (AUS/FLUS) 
(Bethesda category III), follicular neoplasm/suspicious for 
follicular neoplasm (FN/SFN) (Bethesda category IV), and 
Suspicious for malignancy (SM) (Bethesda category V) (7). 
The reported frequency and risk of malignancy with each of 
the Bethesda reporting categories is summarized in Table 1.
Patients and physicians faced with an indeterminate 
cytopathology report will have to make the sometimes 
difficult decision of deciding on the next step in 
management of the thyroid nodule, which until recent 
years has meant choosing from one of three options: repeat 
FNA, observation with continued ultrasound surveillance or 
surgical management. Each of these strategies brings with 
it specific considerations and complexities; for instance 
in patients referred for surgery the need to decide upon 
the extent of thyroidectomy and the potential need for 
a two-step procedure of thyroid lobectomy followed by 
a completion thyroidectomy in the circumstance that the 
lobectomy results in a diagnosis of thyroid cancer. 
Taking into consideration that many thyroid cancers 
are indolent tumors and that many patients may have 
an excellent prognosis even when the diagnosis and 
treatment has been delayed and the fact that most patients 
who undergo thyroidectomy for AUS/FLUS and FN/SFN 
cytopathology will be diagnosed with benign nodules on 
final surgical histopathology, clinicians and patients have 
been left with weighing the risks of a more conservative 
strategy of surveillance with that of the more aggressive 
approach of proceeding to thyroidectomy.
A variety of factors can predict the risk of cancer and aid in 
the decision on optimal management for patients presenting 
with nodules having indeterminate cytopathology; including 
patient risk factors (age, gender, family history, past exposure 
to ionizing radiation), serum TSH level and presence or 
absence of sonographic features suspicious for papillary 
thyroid cancer (PTC) (6,8,9). In their 2015 management 
guidelines pertaining to adults with thyroid nodules, the 
American Thyroid Association (ATA) has provided clear 
guidance on the criteria that should be used to determine 
the initial indication for FNA based on traditional risk factors 
and in particular a risk stratification model heavily reliant 
upon sonographic appearance of the nodule (6). 
However, in the circumstance that FNA is performed, 
once patients and health care providers are faced with 
indeterminate cytology, it becomes much less clear from the 
guidelines precisely how the same criteria should be used 
to inform management decisions. This situation has created 
a need to improve on the cytological inaccuracy inherent 
to the diagnosis of indeterminate thyroid FNA, resulting in 
the development of a number of new diagnostic modalities 
intended for application as a “rule-in” or “rule-out” test for 
thyroid cancer. When discussing the performance of any 
of these tests it must be taken into consideration that the 
ideal ‘rule-in’ test should have a positive predictive value 
(PPV) similar to that of a malignant cytological diagnosis 
Table 1. Bethesda system for the classification of thyroid cytopathology
Bethesda 
category
Cytopathologic 
category
Approximate 
expected frequency
Malignancy rate Suggested treatment (Prior to 
availability of molecular testing)
I Non-diagnostic/Inadequate 5-11% 1-4% Repeat FNA
II Benign 55-74% 0-3% US follow-up
III Atypia/follicular lesion of 
undetermined significance
5-15% 5-15% Repeat FNA or US follow-up or 
Lobectomy
IV Follicular neoplasm/
suspicious for FN
2-25% 15-30% Lobectomy
V Suspicious for malignancy 1-6% 60-75% Lobectomy or Thyroidectomy
VI Malignant 2-5% 97-99% Near-total thyroidectomy
FNA: Fine-needle aspiration, FN: Follicular neoplasm, US: Ultrasonographic
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(Bethesda category VI) (98.6%), while an ideal ‘rule-
out’ test should have a negative predictive value (NPV) 
comparable to that of benign cytology (Bethesda category 
II) (96.3%) (7).
In recent years a number of diagnostic tests have been 
evaluated to aid in the diagnosis of indeterminate thyroid 
nodules, including FDG-PET and several assessments of 
molecular markers in FNA specimens (10,11). Molecular 
tests include immunohistochemistry for Galectin -3, HBME-
1 and CK19; gene expression and microarray analysis; 
microRNA expression; and testing for mutations and gene 
rearrangements (6,12). Currently in the U.S.A. commercially 
available molecular tests include those for single or multiple 
mutation analysis, combination panels for mutation analysis 
and chromosomal rearrangements (miRInform®-Asuragen, 
ThyroSeq-CBLPath and University of Pittsburgh Medical 
Center) and a proprietary gene expression classifier 
(Afirma GEC®-Veracyte) (13,14,15). While initially the 
gene expression classifier (GEC) was proposed as the best 
among these tests to rule-out malignancy and mutation 
analysis was preferred as a “rule-in”, the next-generation 
sequencer (NGS) ThyroSeq has recently been shown to 
have both a high PPV and NPV for thyroid cancer diagnosis 
when applied to thyroid FNA with indeterminate cytology 
(16,17,18). A further strength of the ThyroSeq, when 
compared to GEC, is that it provides detailed and specific 
information regarding the exact genetic alteration driving 
the disease, which could potentially provide prognostic and 
therapeutic implications including impacting upon extent of 
surgery, use of RAI and possible future targeted therapies.
Thyroid cancer, like all cancers, is a disease of the genome. 
The initiation and progression of cancer is due to the 
accumulation of genetic and epigenetic changes such as 
somatic mutations, chromosomal rearrangements, micro 
RNA dysregulation and alterations in gene expression 
(19). In differentiated thyroid cancer (DTC), the observed 
genetic changes frequently lead to activation of the 
MAPK or PI3K-AKT pathways. Approximately 70% of DTC 
demonstrate one of four genetic abnormalities: point 
mutations in the BRAF or RAS gene or either one of two 
chromosomal rearrangements: RET/PTC or PAX8/PPARG 
(19). Our knowledge of the genomic alterations explaining 
the remaining approximately 30% of all thyroid cancers 
not harboring one of the aforementioned four genetic 
aberrations has been greatly expanded by a number of 
recent discoveries, including those reported in 2014 by 
the National Cancer Genome Atlas Research Network, in 
which the genetic driver was identified in 96.5% of 496 
PTC cases (20,21). The findings of this last report have led 
some experts to propose a reclassification of PTCs based on 
molecular characteristics to better reflect their underlying 
differentiation and signaling properties (21). While a 
detailed discussion of all current molecular tests in thyroid 
FNA is beyond the scope of this article, our review will focus 
on the role of NGS, a methodology which we believe may 
hold particular promise in diagnosis of thyroid FNA as well 
as future potential for use in prognostication and informing 
management of patients with thyroid cancer.
Next-generation Sequencing in Thyroid Fine-
Needle Aspiration
NGS is a method of simultaneous sequencing of a very 
large number of short nucleic acid sequences that can be 
used to detect multiple genetic alterations in large regions 
of the genome (22). Compared to standard methods of 
sequencing, such as Sanger sequencing, NGS has the 
advantage of rapid simultaneous sequencing of large 
sections of the genome and quantitative assessment 
of mutated alleles. NGS can be used for whole-genome 
sequencing as well as in a more targeted manner directed 
at specific mutations in specific areas of the genome.
The ThyroSeq NGS panel provides simultaneous sequencing 
for detection in over a thousand hotspots of 14 thyroid 
cancer-related genes and for 42 types of gene fusions 
occurring in thyroid cancer (14,17). The genes analyzed for 
mutation are AKT1, BRAF, CTTNB1, GNAS, HRAS, KRAS, 
NRAS, PIK3CA, PTEN, RET, TP53, TSHR, TERT and EIF1AX. 
The gene list for gene fusions and expression consists of 
RET, PPARG, NTRK1, NTRK3, ALK, IGF2BP3, BRAF, MET, 
CALCA, PTH, SLC5A5, TG, TTF1, KRT7 and KRT20.
The proposed uses for NGS for thyroid FNA samples include 
diagnosis of cytologically indeterminate thyroid nodules, 
prognostication in thyroid cancer and to inform selection 
of targeted therapies (14). The possible applications and 
indications of ThyroSeq include:
1. Thyroid FNA with indeterminate cytology (Bethesda 
categories III, IV and V),
2. Malignant thyroid cytology (Bethesda category VI), 
when results of the NGS are expected to affect the decision 
for extent of oncological surgery,
3. Benign thyroid cytology (Bethesda category II), when 
strong SM exists on clinical grounds such as presence of a 
highly suspicious sonographic pattern,
4. When the diagnosis of thyroid cancer is established 
cytologically or histologically and molecular profiling 
will effect decision regarding radioactive iodine therapy, 
intensity of follow up, or for selection of targeted therapies 
in patients with advanced cancer.
We will discuss the potential roles of NGS in thyroid FNA 
specimens below, with an emphasis on its role in clinical 
decision-making.
Potential Role of Next-Generation Sequencer in 
AUS/FLUS (Bethesda Category III) Cytology
The diagnosis of AUS/FLUS should be made in FNA 
specimens containing cells with architectural and/or 
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nuclear atypia more pronounced than expected for benign 
changes, yet not sufficient to be classified in one of the 
higher risk Bethesda categories (7). Although this diagnosis 
has an expected and recommended frequency of 7%, 
recent analyses have found this cytological category to be 
diagnosed in 1-27% of all thyroid FNA specimens (23). In 
studies assessing the risk of cancer in patients with Bethesda 
category III nodules, the rate of malignancy diagnosed in 
patients who went to surgery was 6-48%, with a mean risk 
of 16% (24).
To date only one study has assessed the performance of 
ThyroSeq in AUS/FLUS (17). In this study 465 FNA samples 
from 441 patients at a single institution diagnosed as AUS/
FLUS on cytology were submitted prospectively to ThyroSeq 
molecular testing. In addition to the 42 gene fusions and 
14 genes analyzed for point mutation, expression of eight 
genes were analyzed to evaluate the cell composition of the 
needle aspirates. Ninenty-eight of the cases (21%) had a 
definitive diagnosis by either surgical (n=96) or non-surgical 
(n=2) methods. Of all FNA samples 462 were determined 
to be composed of follicular cells while three samples were 
diagnosed as parathyroid in origin. Among the samples 
consisting of follicular cells 31 were positive on mutational 
analysis (6.7%) (Figure 1).
Of the entire group of 441 patients, 96 nodules occurring 
in 90 patients were surgically removed due to the finding 
of an additional nodule in the same gland with either 
Bethesda V or Bethesda VI cytology in five patients. 
Twenty-seven patients underwent thyroidectomy because 
of positive ThyroSeq results and the remaining cases were 
Figure 1. Schematic representation of study flow and overall performance of ThyroSeq in thyroid nodules with atypia of undetermined significance/
follicular lesion of undetermined significance. Results showed sensitivity 90.0% [confidence interval (CI) 78.8-100], specificity 92.1% (CI 86.0-98.2), positive 
predictive value 76.9% (CI 60.7-93.1) and negative predictive value 97.2% (CI 78.8-100) with accuracy of 91.8% (CI 86.4-97.3). The overall prevalence 
of a thyroid cancer diagnosis in the study of all samples of follicular cells (n=462) that underwent molecular testing was 4.8%. (Adapted from Nikiforov 
YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Impact of the 
multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of 
undetermined significance cytology. Thyroid 2015;25:1217-1223).
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reported by the authors to have been operated on based on 
patient preference. In all, 98 nodules from 92 patients had 
a definitive diagnosis, either surgical (n=96) or nonsurgical.
It is important to note that the study was conducted in 
a prospective manner, in that the molecular analysis 
was performed prior to the surgery. Therefore, the 
histopathologic diagnosis was provided by pathologists that 
were not blinded to results of the NGS test. Of all FNA 
samples deriving from follicular cells 31 (6.7%) were positive 
for mutations (n=24) or gene fusions (n=7). The most 
common genetic alteration encountered were mutations 
involving RAS (n=17) and only one nodule was found to be 
positive for the BRAFV600E mutation. Of the 31 nodules with 
positive ThyroSeq, 26 were surgically treated while 69 out 
of the total group of 431 mutation negative nodules, were 
subjected to surgical removal. Of the surgeries performed, 
half (n=45) were total thyroidectomies and the remaining 
half underwent hemi-thyroidectomy.
Among the 26 nodules with positive ThyroSeq results that 
underwent surgical treatment, 20 (77%) were ultimately 
deemed to be malignant by histopathology. Eighteen 
were follicular-variant papillary thyroid carcinoma and two 
represented the classic variant of papillary carcinoma. Of the 
six benign nodules that had tested positive for mutations, 
two had NRAS mutation and the others contained single 
mutations each in HRAS, E1F1AX or PTEN with one nodule 
harboring a THADA fusion. On histology, 4 out of the six 
benign nodules harboring mutations were classified as 
follicular adenomas and the other two were deemed to 
represent hyperplastic nodules.
Of the 69 thyroid nodules that were excised after testing 
negative by the next generation-gene sequencer only two 
were malignant on final pathology. Both tumors were 
papillary carcinomas, under two centimeters in diameter, 
confined to the thyroid and did not exhibit lymphovascular 
invasion.
On final analysis of test performance, ThyroSeq provided 
accurate classification of 91 out of 96 nodules in which 
a final surgical diagnosis was available as either benign 
(n=71) or malignant (n=20). Two false-negative and six 
false-positive tests were encountered in the study. Based 
on these findings the performance characteristics of the 
test were quite favorable with a 90.9% sensitivity, 92.1% 
specificity. The NPV was 97.2% and PPV 76.9%.
When interpreting the above performance characteristics 
of the ThyroSeq, it is important to note that while sensitivity 
and specificity are characteristics intrinsic to any test, the 
resulting PPV and NPV values are highly influenced by 
the pre-test probability of the disease, in other words the 
performance characteristics involving predictive value will 
change significantly based on the prevalence of disease in 
the study population. Because the prevalence of malignancy 
among AUS/FLUS that has been reported in the literature 
varies between 6% and 48%, the NPV of the molecular test 
would be expected to range from 99% to 92%, and the 
PPV between 42% and 91%.
Given the high sensitivity of the test for diagnosing thyroid 
cancer and the resultant NPV, which is similar to that 
reported for benign cytology (<5%), it has been proposed 
that a negative ThyroSeq in a patient with AUS/FLUS can 
generally be considered as a basis for observation rather 
than surgery (17). The exception could be a population or 
particular patient or nodule with a high pre-test probability 
for cancer. 
Though the addition of several genetic markers to the 
previously reported seven-gene panel has resulted in 
a decrease of PPV from 88% to 77%, the PPV for the 
ThyroSeq may still be sufficient to consider it not only as a 
rule-out test, but also as a rule-in test for the diagnosis of 
thyroid cancer. A further strength of NGS is that the PPV is 
close to 100% in the case of certain mutations including in 
tumors positive for the most common BRAF mutations and 
for fusions in PPARG, NTRK1, NTRK3 and ALK. One must 
also take into consideration that 3 out of the 6 total “false-
positives” in this study were benign nodules harboring 
RAS mutations. These are clonal neoplasms and there is 
controversy that such tumors could represent pre-malignant 
lesions. In fact, several lines of evidence lend support to the 
hypothesis that RAS is an oncogene responsible for gradual 
progression from benign to malignant thyroid lesions (25).
Though the above described findings are encouraging, 
there are several limitations of the study. The study was 
performed at a single institution and the participants, 
including the patients, clinicians, surgeons and pathologists 
were not blinded to the results of the molecular test. In fact, 
the results of the test were reported to have been used as 
a basis to operate in at least 27 of the cases. The unblinded 
nature of the study could lead to an overestimation of 
the test accuracy, a phenomenon known as review bias 
or expectation bias. Given the very short-term follow-up 
provided and the lack of surgical definitive diagnosis for the 
large number of cases that had negative mutation analysis 
and were not operated on, we cannot know for sure the 
performance characteristics of the test in the entire group 
of patients tested, which consists mainly of patients who 
did not undergo surgery and of which none had long-term 
follow-up at the time of reporting of the study findings. 
Of the 462 nodules of follicular cell composition that were 
submitted for molecular testing only 22 were ultimately 
diagnosed as malignant. Given the lack of long term 
follow up, it is reasonable to question whether some cases 
of thyroid cancer remained undiagnosed among the 367 
nodules that were not surgically treated.
While the authors provided data regarding the rationale 
to proceed to surgery in the group of patients that were 
submitted to thyroidectomy, details regarding the decision-
making process leading to observation in the cohort not 
operated on and therefore not included in the analysis of 
test performance could also be of use in understanding the 
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full implications and the generalizability of the study results. 
What were the sonographic features of the nodules in the 
study? How did they correlate with results of mutation 
analysis and were they used in the decision making process 
to select nodules for surgery and on the extent of surgeries 
performed? What were the baseline characteristics of 
the patients and were other molecular tests such as GEC 
also performed and utilized in the decision to observe vs. 
proceed to surgery? The answers to these questions would 
be helpful in understanding how the results of the study 
could inform every day clinical practice.
Furthermore, while at first glance it appears to be a 
strength of this study that the majority of the patients 
who underwent thyroidectomy did so based on suspicious 
or malignant results of a co-existing nodule other than 
the nodule sampled and included in the analysis for test 
performance, this also may decrease the applicability of 
the test performance to the more common scenario in 
which patients undergo thyroidectomy for diagnosis of 
an indeterminate solitary nodule, without a co-existing 
nodule with a higher risk cytological diagnosis. Thyroid 
cancer, PTC in particular, is often multi-focal and patients 
harboring one malignant thyroid nodule may be more likely 
to have another. Whether the test would perform as well 
in a large cohort of patients with solitary nodules or co-
existing benign nodules is a matter that demands further 
investigation.
To determine the true value of the NGS in clinical decision-
making in this study population it would have also been 
helpful to know the sonographic and other traditional 
thyroid cancer risk factors of all the patients who had 
ThyroSeq testing. It is possible that in a significant number 
of these cases the pre-test probability of cancer may have 
been high (or low) enough to justify surgery or observation 
as the best management strategy, based on for instance 
very high (or low) risk sonographic nodule appearance. 
Also, it is possible that excluding patients who proceeded 
to surgery based on the mutation analysis results or due 
to “patient preference” from the calculations of test 
performance characteristics would have yielded different 
results.
Multi-center studies of ThyroSeq in which practitioners 
and participants are blinded to test results, with long-term 
follow-up including health outcomes data will provide even 
more value in assessing the performance of the ThyroSeq 
and its applicability and utility for “real-world” management 
of thyroid nodules with Bethesda III cytology. However, 
given the already recognized implications of the mutation 
analysis on diagnosis as well as emerging data suggesting its 
use in determining prognosis or selecting among treatment 
options in some cases, it may not be considered ethical, 
even at this early stage of inquiry into the role of molecular 
testing in diagnosing thyroid carcinoma, to withhold results 
of molecular testing from subjects enrolled in such studies. 
Comparison of Utility of Next-Generation 
Sequencer to Other Strategies Recommended for 
the Management of AUS/FLUS Cytology
In regards to the strategy aimed at diagnosing and 
managing patients with a Bethesda category III thyroid 
nodule cytology result, the 2015 ATA guidelines provide 
the following recommendations (6):
“For nodules with AUS/FLUS cytology, after consideration 
of worrisome clinical and sonographic features, 
investigations such as repeat FNA or molecular testing may 
be used to supplement malignancy risk assessment in lieu 
of proceeding directly with a strategy of either surveillance 
or diagnostic surgery. Informed patient preference and 
feasibility should be considered in clinical decision-making 
(weak recommendation, moderate-quality evidence). 
If repeat FNA cytology and/or molecular testing are not 
performed or inconclusive, either surveillance or diagnostic 
surgical excision may be performed for an AUS/FLUS thyroid 
nodule, depending on clinical risk factors, sonographic 
pattern, and patient preference (strong recommendation, 
Low-quality evidence).”
Prior to the availability of molecular testing for FNAs with 
AUS/FLUS cytology, it was recommended to consider 
repeat FNA as one approach to management (26). This was 
based on the observation that approximately 50% of such 
repeat FNAs resulted in benign cytology. However, a recent 
report has described similar rates of malignancy in patients 
undergoing surgery after benign results on repeat FNA and 
those with repeatedly Bethesda category III cytology (27). 
For those patients not wanting to be subjected to a repeat 
FNA procedure a second-opinion review of the original FNA 
specimen by a high-volume cytopathologist may result in 
reclassification and could be a reasonable first-step in some 
instances (28).
Ultrasound features of the nodule with AUS/FLUS cytology 
may be used to aid in improving diagnostic prediction of 
malignity or benignity (29,30). Retrospective studies have 
reported a PPV of 60-100% when suspicious sonographic 
appearance is present. However, these studies are limited 
by the fact that surgical diagnosis was not available for 
the majority of nodules and follow-up was short-term in 
duration. The combination of sonographic characteristics 
and molecular testing in AUS/FLUS has only been reported 
in one study using a GEC and none using mutational 
analysis or NGS (31). While this study did not show any 
benefit in improving prediction provided by the molecular 
testing alone, it may have not been adequately powered. 
Though not commonly performed or recommended in the 
evaluation of thyroid nodules, fludeoxyglucose-positron 
emission tomography (FDG-PET) has been reported to have 
a high NPV when applied to the diagnosis of cytologically 
indeterminate thyroid nodules. In a systematic review and 
meta-analysis of 6 studies FDG-PET had a low PPV (39%) 
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and a high NPV (96%) when performed in thyroid nodules 
with Bethesda category III or IV cytology (10).
While the optimal approach to the diagnosis and 
management of thyroid nodules with AUS/FLUS 
cytopathology remains controversial, molecular tests 
including NGS have been increasingly utilized to provide 
additional information to aid in the decision. In its 2015 
guidelines the ATA conclude “Further research is needed to 
consider the impact of considering clinical and sonographic 
features on the potential utility and interpretation of 
molecular testing of FNA specimens.”
Clinical Utility of Next-generation Sequencing 
in Follicular Neoplasm/Suspicious for Follicular 
Neoplasm (Bethesda Category IV) Cytology
According to the Bethesda system, the diagnosis of FN/
SFN should be made in thyroid aspirates that have follicular 
cells arranged in an architectural pattern characterized by 
cell crowding and/or microfollicle formation and lacking 
nuclear features of papillary carcinoma, or are comprised
almost exclusively of oncocytic (Hurthle) cells (7). These 
cytological patterns are seen with follicular and Hurthle cell 
carcinomas and the follicular variant of papillary carcinoma, 
however they are commonly observed in follicular 
adenomas and in hyperplastic nodules as well. Since such 
benign lesions are
fairly common, they have a high false-positive rate on 
FN/SFN cytology, because only 14-34% of all nodules 
undergoing FNA with FN/SFN cytology are identified as 
malignant on the gold-standard surgical pathology (24).
In a meta-analysis of 8 studies with a total of 25,445 
thyroid FNA samples, 10.1% of the results were reported 
as Bethesda IV with an average 26% rate of thyroid cancer 
diagnosed among these after surgery (32). The typical 
management approach has been to perform diagnostic 
lobectomy for such patients.
Prior to the recent introduction of ThyroSeq, available 
molecular tests improved either the PPV or the NPV for FN/
SFN nodules, but not both at the same time. The GEC test, 
Afirma (Veracyte, South San Francisco, California), offers 
a high NPV, but its PPV is as low as 15% to 37% when 
applied to FN/SFN (33,34). As a result, the GEC may not be 
ideal to use as a basis to avoid diagnostic lobectomy in the 
majority of patients with this cytological diagnosis when 
classified as GEC suspicious, yet ultimately are found to 
have benign histology. The previously reported 7-oncogene 
panel yields a high PPV but a low NPV, which can aid in 
selecting patients with a higher risk of cancer and may 
help the surgeon decide on the appropriate extent of 
surgery, but does not prevent diagnostic surgeries for the 
majority of patients, in which the nodules are eventually 
determined to be benign (35). The low NPV of the 7-gene 
panel is due to the fact that only approximately 70% of 
thyroid cancer harbor a mutation in any of the 7 genes 
tested.
In the largest study of molecular marker testing in FN/SFN 
to date, Nikiforov and colleagues (16) reported findings of 
NGS (ThyroSeq) in 143 patients with FN/SFN cytology all of 
who underwent surgery for definitive diagnosis. The study 
included both a cohort of 91 patients in whom the molecular 
testing was performed retrospectively after surgery and 
final histopathologic diagnosis, as well as a cohort of 52 
consecutive FNA samples studied prospectively in which 
the NGS was performed prior to thyroidectomy. While the 
researchers performing the molecular testing were blinded 
to the results of the surgical pathology, the pathologists 
reporting on the surgical specimens were not blinded 
entirely at the time of their analysis of the specimens. 
The ThyroSeq included testing for 13 mutant genes as 
well as 42 gene fusions known to occur in thyroid cancer. 
Expression of 8 other genes was assessed to confirm the 
cellular composition of the FNA sample.
Among the retrospective cohort (n=91) surgical pathology 
reporting was consistent with 66 benign nodules (35 
follicular adenomas and 31 hyperplastic nodules) and 25 
malignant nodules (Figure 2). The malignancy rate in this 
cohort was 27.5% with 3 FTC and 24 PTC, of which 19 
were follicular variant PTC. The rate of malignancy was 
similar in the prospective cohort at 26.9% with 38 benign 
lesions and 14 malignant lesions, including 11 PTC and 3 
FTC. As expected, a proportion of nodules were found to 
represent Hurthle cell tumors, the frequency of which was 
reported in detail for all groups.
The most frequent mutations identified were that of NRAS 
(n=16) and KRAS (n=6) in which the rate of cancer diagnosed 
on final histology was 81% and 83% respectively. HRAS 
mutation was discovered in two samples, both of which 
were malignant on final analysis. Only 1 out of 3 samples 
harboring a TSH-receptor gene mutation (TSHR) was 
malignant. Several other mutations, though encountered 
less frequently in the cohorts, had a much higher rate of 
malignancy of 100% including 4 out of 4 samples harboring 
TERT mutations and one each in samples with mutations in 
BRAF, TP53 and PI3K. All of the samples identified with 
gene fusions (n=9), were malignant, and involved one of 
the three genes PPARG, THADA and NTRK3.
Analysis of the data revealed no differences in operating 
characteristics among the 2 cohorts; therefore, they were 
combined to assess test performance. In the entire cohort 
of 143 patients, the test performed at a 90% sensitivity 
(95% confidence interval (CI), 80%-99%), 93% specificity 
(95% CI, 88%-98%), an NPV of 96% (95% CI, 92%-100%), 
and a PPV of 83% (95% CI, 72%-95).
Because NPV and PPV are greatly affected by prevalence 
of disease in the test population, the variable rates of 
malignancy for FN/SFN cytology at different institutions 
would be expected to alter predictive values of any test. 
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In the review of 8 studies performed by Bongiovanni 
and colleagues (32), the cancer rate among Bethesda IV 
varied between 14% and 34% which would result in the 
ThyroSeq having a NPV between 98% and 95%, and PPV 
range between 68% and 87%. 
Of note, of the four false-negative results representing 
thyroid malignancies without detected genetic abnormality, 
all four were intra-thyroidal and none had aggressive 
histopathological features. The authors speculated that the 
fact that no aggressive tumors were missed could be due to 
the fact that such tumors often have mutations in TERT, BRAF 
or more than one mutation. Three cancers in the series were 
reported to have more than one mutation. A recent case 
report further underscores the possible implications of the 
detection of multiple mutations and proposes a relationship 
of such a finding to aggressive tumor behavior (36).
Based on the above reported data it could be concluded 
that most patients with thyroid nodules with Bethesda 
IV cytopathology and negative NGS testing could be 
monitored without surgery. Notable exceptions may be 
in settings where the patient population has an unusually 
high prevalence of thyroid cancer or in individual patients 
in which the pre-test probability of cancer is exceptionally 
high due to other predictive factors such as family history, 
prior irradiation or high-risk sonographic characteristics 
of the nodule. In those unusual clinics having a high 
prevalence of thyroid cancer above 50% among their FN/
SFN patient population, indeed the NPV of ThyroSeq would 
be below 90% and this could be considered too low to 
avoid diagnostic lobectomy.
The 2015 ATA guideline pertaining to the management 
of the patient with a thyroid nodule and FN/SFN cytology 
recommends:
“A) Diagnostic surgical excision is the long-established 
standard of care for the management of FN/SFN cytology 
nodules. However, after consideration of clinical and 
Figure 2. Schematic representation of study flow and overall performance of ThyroSeq in thyroid nodules with follicular neoplasm/suspicious for follicular 
neoplasm. Results showed sensitivity 90% [confidence interval (CI) 80-99], specificity 93% (CI 88-98%), positive predictive value 83% (CI 72-95) and negative 
predictive value 96% (CI 92-95) with accuracy of 92% (CI 88-97). (Adapted from Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding 
WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Highly accurate diagnosis of cancer in thyroid nodules with follicular 
neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627-3634).
FN/SFN: Follicular neoplasm/suspicious for follicular neoplasm
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sonographic features, molecular testing may be used 
to supplement malignancy risk assessment data, in lieu 
of proceeding directly with surgery. Informed patient 
preference and feasibility should be considered in clinical 
decision-making (weak recommendation, moderate-quality 
evidence).
B) If molecular testing is either not performed or 
inconclusive, surgical excision may be considered for 
removal and definitive diagnosis of an FN/SFN thyroid 
nodule (strong recommendation, low-quality evidence)”.
Recommendations on the Use of Next-generation 
Sequencing from Clinical Practice Guidelines
In 2015 the ATA published revised guidelines on the 
management of adult patients with thyroid nodules and 
thyroid cancer (6). These guidelines included a thoughtful 
and detailed discussion of the potential role of molecular 
testing in the diagnosis of thyroid nodules and their 
implications for the management of patients with thyroid 
nodules and cancer. It should be noted that though the 
guideline included discussion of the previously reported 7 
gene mutational analysis panel and the published reports of 
ThyroSeq in FN/SFN cytology, the more recent publication 
regarding performance of ThyroSeq in AUS/FLUS was 
not available at the time of publication of the 2015 ATA 
guidelines.
The authors of the ATA guidelines created a framework 
for the use of molecular testing including a classification 
of such tests according to intended use as either for 
diagnostic purposes (for classification of a disease state), 
prognostic or predictive purposes (to provide predictive 
information regarding the probability of benefit or harm of 
a specific treatment) (37). The ATA authors emphasize that 
since there is a lack of long-term outcomes data regarding 
the use of molecular testing to guide therapeutic decision-
making, it remains unknown whether routine use of such 
tests in clinical practice would result in a net benefit in the 
health of patients with thyroid nodules and thyroid cancer. 
Similarly, a National Comprehensive Cancer Network task 
force report has declared that the clinical utility of any 
molecular test must be based on strong evidence that 
use of the test “improves patient outcomes sufficiently to 
justify its incorporation into routine clinical practice” (37).
Taking into account the above principles, the ATA guidelines 
recommend that the current use of molecular marker testing 
for patients with indeterminate thyroid nodule cytology is 
primarily diagnostic (to rule in or rule out malignancy), with 
an added implication of a companion use to aid in decision-
making on initial surgical management (the decision to 
perform surgery and to guide the extent of surgery).
The 2015 ATA guidelines also point out that while previously 
published guidelines, including the ATA statement on 
surgical application of molecular profiling of thyroid 
nodules, were written at a time when total or near-total 
thyroidectomy was recommended as the initial surgical 
procedure for most cases of thyroid cancer, the current 
guidelines suggest more conservative surgical management 
(i.e., hemi-thyroidectomy) be considered as an option for 
low-risk thyroid cancer (38). This change could affect the 
utility of the result of NGS to determine extent of surgery 
for patients with indeterminate cytology and positive 
mutational analysis. Furthermore, there are no long-term 
outcome data testing the strategy of using NGS or other 
molecular tests in indeterminate FNA specimens to stratify 
surgical approach.
In summary the 2015 guidelines of the ATA provide the 
following recommendation: “If molecular testing is being 
considered, patients should be counseled regarding the 
potential benefits and limitations of testing, and about 
the possible uncertainties in the therapeutic and long-term 
clinical implications of results”.
Potential Use of Mutational Analysis for 
Prognostication and Targeted Therapy of Thyroid 
Cancer
A strength of NGS when applied as a diagnostic test 
to patients with thyroid nodules and thyroid cancers is 
the potential impact that knowledge of the underlying 
genetic anomaly could have on prognostication and 
implications for treatment decisions. Mutations involving 
AKT1, TP53, PIK3CA and CTNNB1 are rarely present in 
benign thyroid nodules and common in more advanced 
thyroid cancers (39). TERT mutations in particular have 
been associated with increased disease specific mortality, 
distant metastasis and radioactive iodine refractory 
disease (40,41,42). BRAFV600E mutations are associated 
with higher recurrence rates and mortality in thyroid 
cancer (43). However, it remains controversial whether 
mutational status provides further prognostic information 
to that already provided by more traditional prognostic 
factors such as patient characteristics and grade and 
stage of disease at presentation. For thyroid papillary 
microcarcinoma evidence suggested that BRAF status 
together with several histopathologic features was a 
better predictor of extrathyroid tumor spread than either 
mutation or histopathologic findings alone (44).
It is likely that with increasing application of mutational 
analysis in thyroid nodules and cancers, and analysis of 
prospective studies of its use will provide data to answer 
this question in the future.
It must also be taken into consideration that while factors 
inherent to the tumor, including mutation status, have effects 
on prognosis; “host factors” involving the patient harboring 
the tumor may independently, or via complex interactions 
with the genomic alterations of the tumor have effects on 
tumor behavior and prognosis. Underscoring this point is a 
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recent report associating obesity with increased prevalence 
of BRAFV600E mutations among patients with PTC (45).
Targeted therapies directed by results of mutational 
analysis are recommended for a variety of cancers. 
Treatment of melanoma based on BRAF status and 
assessment of KRAS mutational status to determine 
medical treatment for colorectal cancer are strategies 
that have been tested in clinical trials (46,47). While 
targeted therapy based on mutational analysis is not 
yet a widely accepted practice for thyroid cancer 
there are several clinical trials in progress to test this 
hypothesis. Clinical trials of MEK or BRAF inhibitors to 
increase radioiodine uptake for patients with BRAF-
mutant, RAI-refractory thyroid carcinoma (ClinicalTrials.
gov Identifier: NCT02145143) and RAS mutated thyroid 
cancer (ClinicalTrials.gov Identifier: NCT02152995) 
are underway. Studies of combination of BRAF 
and MEK inhibitors for patients with BRAF mutant 
anaplastic thyroid cancer (ClinicalTrials.gov Identifier: 
NCT02034110) are also enrolling patients. Patients with 
advanced thyroid cancers harboring PAX8/PPARγ fusions 
(ClinicalTrials.gov Identifier: NCT01655719) and NTRK 
alterations (ClinicalTrials.gov Identifier: NCT02122913) 
are now being treated in clinical trials. Previous data 
showed that STRN-ALK fusions occur more often with 
aggressive types of thyroid cancer and several reports 
have demonstrated that patients with advanced thyroid 
cancer with ALK fusions may benefit from ALK inhibitors 
such as Crizotinib (48). Not previously seen in thyroid 
cancer, a mutation in the TSC2 and in the mTOR protein 
was discovered in a patient with metastatic anaplastic 
thyroid cancer who initially achieved a near-complete 
response to Everolimus with posterior resistance and 
progression of the disease. This shows the possible 
benefit of sequencing a patient’s cancer DNA prior to 
treatment and following disease recurrence, which may 
help guide treatment in patients with similar mutations 
(49).
Conclusion
As a comprehensive genome atlas of thyroid cancer 
is rapidly becoming a reality, and with emerging 
methodologies such as NGS providing detailed genetic 
information regarding thyroid tumors, we have now 
entered into the genomic age of diagnosis and treatment 
of thyroid nodules and thyroid cancer. Several molecular 
tests are now available to assist in the diagnosis of thyroid 
nodules among which NGS appears to be a particularly 
promising tool that could most accurately characterize the 
genetic alterations underlying these neoplasms. ThyroSeq 
for targeted detection of mutation has been tested for 
its accuracy and performance in diagnosing malignancy 
among thyroid nodules with indeterminate cytopathology 
in two single-center studies and found to have both high 
NPV and an improved PPV when compared to existing 
molecular tests. Large-scale multi-center studies are needed 
to validate these preliminary findings. Furthermore, future 
studies are needed to determine the optimal use of NGS 
in clinical-decision making for patients with indeterminate 
cytopathology after thyroid FNA. Several studies and reports 
point to the potential impact that knowledge of mutational 
status of thyroid tumors can have on prognostication and 
selection of targeted-therapies, though it remains to be 
elucidated whether strategies to treat thyroid cancer based 
on mutational status will improve overall outcomes. As 
we look ahead to the era of “personalized medicine” NGS 
appears to hold promise as a potentially useful tool in the 
detection of thyroid malignancy as well as a possible aid for 
the clinician in determining optimal treatment for patients 
with thyroid neoplasia.
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